Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954
- 22 November 2001
- journal article
- Published by Springer Nature in Oncogene
- Vol. 20 (53) , 7797-7803
- https://doi.org/10.1038/sj.onc.1204954
Abstract
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.Keywords
This publication has 28 references indexed in Scilit:
- The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promotersGene Therapy, 2001
- Telomerase and cancerHuman Molecular Genetics, 2001
- Telomerase inhibitorsPublished by Elsevier ,2001
- Use of Transcriptional Regulatory Sequences of Telomerase (hTER and hTERT) for Selective Killing of Cancer CellsMolecular Therapy, 2000
- Transcriptional control: an essential component of cancer gene therapy strategies?Advanced Drug Delivery Reviews, 2000
- A Novel Telomerase-Specific Gene Therapy: Gene Transfer of Caspase-8 Utilizing the Human Telomerase Catalytic Subunit Gene PromoterHuman Gene Therapy, 2000
- Is small cell lung cancer the perfect target for anti-telomerase treatment?Carcinogenesis: Integrative Cancer Research, 1999
- Cloning and characterization of human and mouse telomerase RNA gene promoter sequencesOncogene, 1998
- Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridizationOncogene, 1998
- Nitroreductase activation of DB1954 – an alternative ‘suicide’ gene systemGene Therapy, 1997